- Home
- ASO vs APGE Comparison
ASO vs APGE Comparison
Compare ASO & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASO
- APGE
- Stock Information
- Founded
- ASO 1938
- APGE 2022
- Country
- ASO United States
- APGE United States
- Employees
- ASO N/A
- APGE N/A
- Industry
- ASO Recreational Games/Products/Toys
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ASO Consumer Discretionary
- APGE Health Care
- Exchange
- ASO Nasdaq
- APGE Nasdaq
- Market Cap
- ASO 2.5B
- APGE 2.1B
- IPO Year
- ASO 2020
- APGE 2023
- Fundamental
- Price
- ASO $39.22
- APGE $37.29
- Analyst Decision
- ASO Buy
- APGE Strong Buy
- Analyst Count
- ASO 18
- APGE 4
- Target Price
- ASO $58.00
- APGE $91.33
- AVG Volume (30 Days)
- ASO 1.4M
- APGE 545.3K
- Earning Date
- ASO 06-10-2025
- APGE 05-20-2025
- Dividend Yield
- ASO 1.31%
- APGE N/A
- EPS Growth
- ASO N/A
- APGE N/A
- EPS
- ASO 5.73
- APGE N/A
- Revenue
- ASO $5,933,450,000.00
- APGE N/A
- Revenue This Year
- ASO $4.71
- APGE N/A
- Revenue Next Year
- ASO $6.78
- APGE $743.14
- P/E Ratio
- ASO $6.91
- APGE N/A
- Revenue Growth
- ASO N/A
- APGE N/A
- 52 Week Low
- ASO $33.34
- APGE $26.20
- 52 Week High
- ASO $64.62
- APGE $63.50
- Technical
- Relative Strength Index (RSI)
- ASO 48.62
- APGE 52.37
- Support Level
- ASO $37.01
- APGE $34.38
- Resistance Level
- ASO $40.37
- APGE $41.05
- Average True Range (ATR)
- ASO 1.28
- APGE 2.23
- MACD
- ASO 0.60
- APGE 0.10
- Stochastic Oscillator
- ASO 73.98
- APGE 51.48
About ASO Academy Sports and Outdoors Inc.
Academy Sports and Outdoors Inc is engaged in the full-line sporting goods and outdoor recreation retailer in the United States. The company's product categories are outdoors, apparel, sports & recreation, and footwear.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.